Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2011

View Archived Issues

New clinical data presented on brentuximab vedotin

Selective ROCK-2 inhibitors presented by University of Michigan

Targeted secretion inhibitors SXN-101000 and SXN-101742 inhibit growth hormone secretion in vivo

Aliskiren shows efficacy in children with hypertension

New GPR119 receptor agonists claimed by Pfizer

Researchers at GSK present new antimalarial agents

Novel muscarinic acetylcholine M1 receptor modulators disclosed

Merck KGaA presents new HSP 90 inhibitors

Cubist Pharmaceuticals reports phase II data on CXA-201 and CB-183315

FDA committee recommends approval of VEGF Trap-Eye for wet AMD

Photocure begins enrolling women with CIN due to HPV infection in phase II Cevira trial

Yeast-based vaccine GI-6207 is safe in phase I trial in metastatic cancer expressing CEA

Fostamatinib disodium improves quality of life in subjects with active rheumatoid arthritis

Pentraxin-related protein PTX3 described as novel biomarker in advanced pancreatic cancer

Takeda begins phase III study of TAK-816 vaccine in Japan

Sunshine Biopharma and the Jewish General Hospital to collaborate on Adva-27a

National Eye Institute awards grant to Cedars-Sinai to develop stem cell therapies

LMS-611 obtains European orphan drug status in cystic fibrosis

Azellon to conduct phase I stem cell trial in the U.K. for meniscal tears

Wilex provides update on the Redectane approval process

Theratechnologies seeks approval for Egrifta in Canada

NovaBay and Alcon terminate Aganocides collaboration and license agreement

GTx begins phase IIb trial comparing Capesaris to Lupron Depot in advanced prostate cancer

FDA approves new 6-month formulation of Lupron Depot for advanced prostate cancer

Chelsea Therapeutics reports encouraging results from QTc interval study of Northera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...